Despite the safety of ACE inhibitors and ARB use in large cohorts of patients with COVID‐19, specific subgroups of patients with particularly high cardiac ACE2 expression may be at increased risk of myocarditis if pharmacological ACE inhibition use further increases cardiac membrane‐bound ACE2 levels. Here, ACE2 is linked to myocarditis.